About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT04608253

A Retrospective Analysis of the Diagnostic Performance of 11C-choline PET/CT in Primary Hyperparathyroidism

The leading cause of primary hyperparathyroidism (pHPT) is a solitary adenoma (89%). The treatment of pHPT is generally surgical removal of the overactive parathyroid gland(s). Since a solitary adenom...

Lead sponsor: University Medical Center Groningen•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

University Medical Center Groningen

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients eligible for inclusion were ≥18 years old, diagnosed with biochemically confirmed pHPT, underwent a MIBI-SPECT/CT and/or cUS with negative or discordant results, and underwent a 11C-choline PET/CT followed by parathyroidectomy.

Exclusion Criteria

•Patients were excluded if they were known to have a germline mutation predisposing for familial hypocalciuric hypercalcemia (FHH).

Related studies

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

NCT03039439 · Parathyroid Gland Adenoma, Parathyroid Gland Atypical Adenoma, and more

Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients

NCT06523582 · Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract, and more

Active Not Recruiting

Glycemic Control, Type II Diabetes, Parathyroidectomy

NCT05761743 · Primary Hyperparathyroidism, Type 2 Diabetes

Surgery for Primary Hyperparathyroidism (pHPT) in Patients Older Than 65 Years Compared With Follow-up

NCT01087619 · Primary Hyperparathyroidism

Not Yet RecruitingPhase 2/3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

NCT07444723 · Primary Hyperparathyroidism, Parathyroid Cancer, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 16, 2024Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment36

Start dateJan 2015

Last updatedApr 16, 2024

Condition

Primary Hyperparathyroidism Primary Hyperparathyroidism Due to Adenoma

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 16, 2024Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions